marked.bio

Company

Kura Oncology

5 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

ziftomenib 4venetoclax 2gilteritinib 1cabozantinib 1adagrasib 1quizartinib 1

Trials

5 of 9 trials shown

  1. Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

    Recruiting Phase 3 Kura Oncology Started 2025Primary completion 2031-11 NCT07007312

    ziftomenib FDAvenetoclaxazacitidinedaunorubicincytarabine

    …nintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

    NPM1 mutationAcute Myeloid Leukemia (AML)

  2. First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

    Active, not recruiting Phase 1/2 Kura Oncology Started 2019Primary completion 2028-10 NCT04067336

    ziftomenib FDAmidazolamitraconazole

    Patients with a documented nucleophosmin 1 mutation (NPM1-m)

    NPM1 mutationAdvanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia

  3. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Recruiting Phase 1 Kura Oncology Started 2024Primary completion 2026-12 NCT06001788

    ziftomenibfludarabineidarubicincytarabinegilteritinib FDA EUGranulocyte colony-stimulating factor

    Has a documented FLT3 mutation (cA-3 only).

    FLT3 mutation (ITD/TKD)NPM1 mutationAML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar

  4. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Recruiting Phase 1 Kura Oncology Started 2023Primary completion 2027-01 NCT06026410

    Darlifarnibcabozantinibadagrasib FDA EU

    …eceived at least 1 prior systemic therapy including available approved SOC treatments for KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC.

    KRAS G12CKRAS G12DSolid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)

  5. A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

    Recruiting Phase 1 Kura Oncology Started 2023Primary completion 2030-04 NCT05735184

    ziftomenibvenetoclaxazacitidinedaunorubicincytarabinequizartinib FDA EU

    Those intending treatment with intensive chemotherapy in Arm C should be NPM1-m and FLT3-ITD+ with an allelic ratio ≥0.05 and eligible for FLT3-targeted treatment

    FLT3 mutation (ITD/TKD)NPM1 mutationAcute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1